A world-first answer for healthy people over 70

A world-first Australian-led trial finds that daily cholesterol-lowering statins can cut heart attack or stroke risk in otherwise healthy people over 70, with low serious side-effect risk, The Guardian reports. The result is not a laboratory curiosity. It is a large, randomized test of a pill already sitting in millions of bathroom cabinets, aimed at a group doctors have long treated with more caution than evidence: older adults who have not yet had a major heart event.

That framing matters. Heart attack and stroke are not abstract endpoints in this population. They are the events that end independence, fill hospital wards, and, too often, end lives. The new work says a daily statin, taken for nearly six years, reduced the chance of a first such event by 30% among people over 70 who were otherwise healthy. The serious harms that have haunted public argument about these drugs did not dominate the safety picture as reported.

The study is Australian-led. It is described as a world-first of its kind: a dedicated look at statin benefit in healthy older people rather than an after-the-fact slice of a trial built for younger patients. The Guardian is the outlet carrying the account used here. The science itself now sits in a premier medical journal and on a major cardiology stage, which is how findings of this type usually move from campus to clinic.

What was already known—and what was not

Statins are already common under 75 for diabetes or high cholesterol and after major heart events at any age. That sentence is the standard of care in compressed form. If you are younger than seventy-five and you have diabetes, or your cholesterol is high, a statin is ordinary medicine. If you have already had a heart attack or a stroke, a statin is ordinary medicine at any age. Secondary prevention—treatment after the disaster—has not been the puzzle.

The puzzle was primary prevention in later life. The benefit for healthy over-70s without prior events was unclear. Unclear does not mean the drugs were proven useless. It means guidelines and clinicians were working without a clean randomized answer for people who had aged past seventy, kept their arteries quiet so far, and did not already carry a diagnosis that would have put them on a statin under existing rules.

Age itself complicates the guesswork. Arteries stiffen. Risk accumulates. A seventy-two-year-old who has never had a heart attack is not a forty-two-year-old with the same cholesterol number. Treating that person as if they were young can look aggressive. Leaving them untreated because the trial evidence stopped at a younger cutoff can look timid. The gap was not philosophical. It was empirical. Until a large randomized comparison existed, both caution and enthusiasm were under-informed.

The new trial was built to close that gap. It did not ask whether statins work after a heart attack. It asked whether daily use in otherwise healthy people over 70—people without prior events—would change the rate of a first heart attack or stroke, and whether it would do so with a low serious side-effect risk.

How Monash ran the trial

Monash researchers randomized nearly 10,000 adults over 70 to daily statin or placebo. Randomization is the feature that separates this from clinic anecdote. Each person was assigned by chance, not by a doctor’s hunch, to the cholesterol-lowering drug or to a matching dummy pill. Over a long follow-up, differences in heart attacks and strokes can then be attributed to the assignment rather than to who seemed frail, motivated, or already well.

Enrollment was not a handful of tertiary-hospital volunteers. Participants were enrolled via almost 3,400 Australian GPs. That design choice is as important as the head count. General practice is where healthy older adults actually receive preventive medicine. A trial that recruits through almost 3,400 community doctors is reaching the setting in which a future guideline would have to live. It is also how a study of this size becomes feasible: nearly 10,000 people over 70 do not walk into a single academic clinic.

The comparison was simple on purpose. One group took a daily statin. The other took placebo. There is no third arm in the account, no cocktail of extra heart drugs layered on as the experimental contrast. The question was the statin itself, taken every day, in people who were otherwise healthy and older than seventy.

Follow-up lasted nearly six years. Preventive cardiology is slow work. A heart attack that does not happen in month three is not yet a result. Nearly six years is long enough for first events to accumulate in a cohort this large, and long enough for dropout, side effects, and competing illnesses to show themselves. It is also long enough that a 30% relative reduction, if real, becomes a number clinics can use rather than a statistical flicker.

Thirty percent fewer first events

Over nearly six years, first major cardiovascular events fell 30%. The wording is precise. These were first events, not a mix of second and third catastrophes in people who already had coronary disease. Major cardiovascular events in this reporting are the outcomes that matter at the kitchen table: heart attack or stroke. The statin group had fewer of them. The reduction was 30%.

Relative risk can mislead when the starting risk is tiny. The trial report, as carried, translates the finding into a number clinicians already know how to use: one event prevented per 37 older adults treated. That is the number-needed-to-treat. Treat 37 otherwise healthy people over 70 with a daily statin, on this evidence, and you prevent one first major cardiovascular event over the follow-up. Thirty-six people take the pill without being the one whose heart attack or stroke is averted. One does not.

Whether that trade looks attractive depends on the low serious side-effect risk the trial found and on how a patient values a first heart attack or stroke that never arrives. It is not a miracle ratio from an intensive-care drug. It is the kind of ratio preventive medicine accepts when the treatment is a daily tablet, the harm signal is low, and the event being prevented is disabling or fatal. It is also not a promise that every older adult must start a statin tomorrow. It is a measured yield from a world-first randomization.

The events themselves are heart attack or stroke—the two outcomes named in the trial’s public summary. A first heart attack can mean a stent, a weakened pump, or death. A first stroke can mean a lost word, a lost limb, or a lost life. Cutting those first events by 30% in people who were healthy at the start is the claim. It is not a claim about reversing existing damage. These participants were selected as people without prior events.

Age as the biggest risk driver

Co-author Adjunct Prof Mark Nelson stressed age as the biggest risk driver. That is the conceptual spine of treating healthy people over seventy at all. Cholesterol, diabetes, and blood pressure still matter. In this argument, age outranks them as the force that pushes a first event from possible to probable. If age is the biggest risk driver, then waiting for diabetes or a sky-high cholesterol reading—or waiting for the heart attack itself—means waiting through the years when risk is already high.

Nelson’s point is not a new physiology. Arterial disease is cumulative. Calendar age is a summary of that accumulation when a person has lived past seventy without a clinical event. The trial’s population is defined by that age line. The benefit showed up there, in otherwise healthy people over 70, which is consistent with treating age as a reason to consider a statin rather than a reason to withhold one.

Lead Adjunct Prof Sophia Zoungas hopes guidelines update. Guidelines are the documents that tell general practitioners when a statin is indicated, optional, or not worth starting. For years those documents have been firmer under 75 for diabetes or high cholesterol and firm after major heart events at any age. They have been less firm for the healthy older person. Zoungas’s hope is that this randomization—nearly 10,000 people, almost 3,400 GPs, nearly six years, a 30% drop in first events—will be enough to rewrite that weaker paragraph.

A guideline update would not be a press release. It would be a change in who gets offered a daily tablet in ordinary Australian (and, later, international) primary care. That is why the recruitment path through general practice is not a footnote. If the people who enroll patients are the same GPs who will later follow an updated guideline, the trial is already speaking the language of the clinic.

The findings were published in the New England Journal of Medicine and presented at the European Society of Cardiology Congress in Germany. Those two venues are how a preventive-cardiology result becomes impossible to ignore. The New England Journal of Medicine is where large outcome trials go when the editors judge the methods and the stakes sufficient. The European Society of Cardiology Congress is the annual gathering at which cardiologists hear the same data from the podium, in Germany in this case, and argue about what to do on Monday morning. Publication plus presentation is the dual track that moves a world-first Australian-led trial from Monash into the guideline committees Zoungas hopes will update.

Dementia, disability, and who stopped the pill

Not every outcome moved. Cardiologist Prof Tom Marwick said dementia rates did not differ—countering misinformation—but disability-free survival was unchanged and over 15% discontinued therapy.

The dementia result is the one that will travel farthest outside cardiology. A persistent strand of misinformation has held that statins fog the mind or raise dementia risk. In this trial, as Marwick reported it, dementia rates did not differ between the groups. The study does not, in this account, claim that statins prevent dementia. It claims they did not produce a detectable excess—or a detectable benefit—on that outcome. For a drug meant to be taken daily for nearly six years by people over 70, a null finding on dementia is a safety result, not a cognitive-enhancement claim. It is also a direct reply to the rumor that has kept some older patients, and some families, away from a tablet that lowers heart attack and stroke risk.

Disability-free survival was unchanged. That is a harder sentence for advocates of universal late-life statins. Preventing one event per 37 treated people is not the same as stretching the years lived without disability. Heart attack and stroke are not the only paths into disability at this age. If the composite of survival without disability did not move, the trial is saying something modest and important at once: fewer first major cardiovascular events, not a proven expansion of years lived free of all disability.

Then there is persistence. Over 15% discontinued therapy. More than one in seven people did not stay on the assigned treatment. Discontinuation is not itself a serious side effect. It is a real-world friction: pills not taken, appointments missed, symptoms blamed on the drug, or a simple decision to stop. In a trial with low serious side-effect risk, a discontinuation rate over 15% still means the 30% event reduction was achieved in a population where a sizable minority did not complete the course. Effectiveness in a GP’s office will depend on how many patients stay on a daily statin for years, not only on the intention-to-treat percentage from a journal table.

Marwick’s three points belong together. Dementia rates did not differ, which undercuts a scare. Disability-free survival was unchanged, which undercuts a miracle narrative. Over 15% discontinued therapy, which undercuts the fantasy of perfect adherence. The heart-attack-and-stroke benefit sits in the middle of that more complicated picture, not in place of it.

What the result does—and does not—change

Taken as reported, the trial changes the evidence for a specific person: someone over 70, otherwise healthy, without prior events, deciding whether a daily cholesterol-lowering statin is worth taking. For that person, the Australian randomization says first major cardiovascular events fell 30%, one event is prevented per 37 older adults treated, and serious side-effect risk was low. Age, Nelson stressed, is the biggest risk driver. Zoungas hopes that is now enough for guidelines to update.

It does not erase what was already true. Statins remain common under 75 for diabetes or high cholesterol. They remain indicated after major heart events at any age. Those uses were not waiting on this study. What was waiting was the healthy older adult—the patient who aged past seventy without a coronary or cerebral catastrophe and without a diagnosis that would have started the pill automatically.

It also does not rewrite every outcome that patients fear or hope for. Dementia rates did not differ. Disability-free survival was unchanged. Over 15% discontinued therapy. Those are not fine print. They are part of the same result. A doctor who cites the 30% reduction without the null dementia comparison, the unchanged disability-free survival, and the discontinuation rate is not using the trial that Monash researchers actually ran.

The geography of the evidence is Australian and the audience is global. Nearly 10,000 adults over 70 came in through almost 3,400 Australian GPs. The paper is in the New England Journal of Medicine. The podium was the European Society of Cardiology Congress in Germany. The Guardian reported the package as a world-first. That combination—community recruitment, a general-medicine journal of record, a cardiology congress, a newspaper account—is how a preventive finding is supposed to travel.

For now the clinical sentence is short enough to fit a consultation and long enough to be honest. In otherwise healthy people over 70, a daily statin cut heart attack or stroke risk. The reduction was 30%. The yield was one event per 37 treated. Serious side effects were low. The mind, as measured by dementia rates, did not pay a detectable price. Years without disability did not measurably grow. More than 15% stopped the drug. Guidelines, if they update as Zoungas hopes, will have to carry all of those clauses, not only the headline 30%.